10-Q: OneMedNet Corporation Reports Third Quarter 2024 Results Amidst Financial Challenges

OneMedNet Corporation's Q3 2024 results reveal a net loss and declining revenue, alongside strategic shifts and financial restructuring efforts.

Summary

• OneMedNet Corporation reported a net loss of $2.1 million for the three months ended September 30, 2024, and a net loss of $7.8 million for the nine months ended September 30, 2024.
• The company's revenue decreased by 56% in the third quarter compared to the same period last year, with subscription revenue down 60% and web imaging revenue down 43%.
• For the nine months ended September 30, 2024, total revenue decreased by 9% compared to the same period last year, with subscription revenue down 26% and web imaging revenue up 102%.
• The company's cost of revenue increased to 159% of revenue in Q3 2024, compared to 90% in Q3 2023, and to 141% for the nine months ended September 30, 2024, compared to 119% for the same period last year.
• General and administrative expenses increased by 42% in Q3 2024 and 99% for the nine months ended September 30, 2024, primarily due to increased professional fees associated with being a public company.
• The company has been strategically investing in Bitcoin, holding $2.2 million as of September 30, 2024.
• The company has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, which includes a $1.5 million convertible promissory note.
• The company has raised approximately $6.3 million through private placements during the nine months ended September 30, 2024.
• The company's cash and Bitcoin balance of $1.9 million and $2.2 million, respectively, is not adequate to fund its operations through at least twelve months from the date these condensed consolidated financial statements were available for issuance.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including declining revenue, high costs, and a going concern risk. While there are some positive aspects, such as the growth in web imaging revenue and recent funding, the overall tone is negative due to the company's financial instability and operational issues.

Positives

• Web imaging revenue increased by 102% for the nine months ended September 30, 2024, indicating growth in the iRWD product line.
• The company has secured $6.3 million in funding through private placements, providing capital for operations.
• The company has strategically invested in Bitcoin, which could potentially provide future financial benefits.
• The company has implemented a compensation recovery policy to recoup incentive-based compensation in the event of an accounting restatement.

Negatives

• The company experienced a significant decrease in subscription revenue, down 60% in Q3 2024, due to the planned discontinuation of the BEAM platform.
• The company's cost of revenue as a percentage of revenue increased significantly, indicating reduced profitability.
• The company's cash and Bitcoin balance is insufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern.
• The company has incurred significant losses, with a net loss of $2.1 million for Q3 2024 and $7.8 million for the nine months ended September 30, 2024.
• The company has material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and insufficient cash reserves.
• The company's reliance on additional financing through equity or debt offerings is subject to market conditions and investor sentiment.
• The company's investment in Bitcoin exposes it to the volatility and risks associated with crypto assets.
• The company's failure to file a registration statement with the SEC for the resale of shares issued under the SEPA has resulted in an event of default.
• The company has material weaknesses in its internal control over financial reporting, which could lead to errors in financial statements.

Future Outlook

The company plans to raise additional working capital through equity or debt offerings and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. The company is also transitioning away from the BEAM platform to focus on iRWD sales.

Management Comments

• Management intends to raise cash for operations through debt and equity offerings.
• Management is aware of material weaknesses in the Company's internal control related to user access/segregation of duties, lack of a formalized control environment and oversight of controls over financial reporting, errors in accounting for non-routine transactions, and lack of record keeping.

Industry Context

The company operates in the healthcare software industry, which is characterized by rapid technological advancements and intense competition. The company's strategic shift from the BEAM platform to iRWD reflects a focus on higher-growth areas within the industry. The company's financial challenges highlight the difficulties faced by smaller companies in this competitive landscape.

Comparison to Industry Standards

• The company's revenue decline and high cost of revenue are concerning when compared to industry benchmarks for healthcare software companies.
• Many established healthcare software companies have higher gross margins and more stable revenue streams.
• The company's reliance on private placements and convertible debt for funding is not typical of more mature companies in the sector.
• The company's investment in Bitcoin is unusual for a healthcare software company and introduces additional risk.
• The company's material weaknesses in internal controls are a significant concern and need to be addressed to meet industry standards for financial reporting.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently party to any legal proceedings that, in the opinion of management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.

Related Party Transactions

• The company issued PIPE Notes to related party investors for $1.0 million.
• The company issued Convertible Promissory Notes to related party investors for $12.3 million.
• The company received gross proceeds of $1.6 million in connection with shareholder loans with a related party investor which are convertible into 2,123,312 shares of Common Stock at a conversion price of $ 0.7535 per share.
• The company received gross proceeds of $0.4 million in connection with non-convertible shareholder loans with related party investors during the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders are at risk of dilution due to potential equity offerings and the conversion of convertible notes.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may experience disruptions due to the company's strategic shift and financial challenges.
• Creditors are at risk due to the company's going concern issues and potential defaults.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company needs to file a registration statement with the SEC for the resale of shares issued under the SEPA.
• The company needs to continue its strategic shift from the BEAM platform to iRWD sales.

Key Dates

Keywords

OneMedNet, financial results, quarterly report, revenue, net loss, Bitcoin, private placement, convertible note, SEPA, internal controls, going concern, healthcare software, medical imaging, iRWD, BEAM